Journal of Cardiovascular Pharmacology and Therapeutics http://cpt.sagepub.com/

The Therapeutic Role of Niacin in Dyslipidemia Management William E. Boden, Mandeep S. Sidhu and Peter P. Toth J CARDIOVASC PHARMACOL THER 2014 19: 141 originally published online 20 December 2013 DOI: 10.1177/1074248413514481 The online version of this article can be found at: http://cpt.sagepub.com/content/19/2/141

Published by: http://www.sagepublications.com

Additional services and information for Journal of Cardiovascular Pharmacology and Therapeutics can be found at: Email Alerts: http://cpt.sagepub.com/cgi/alerts Subscriptions: http://cpt.sagepub.com/subscriptions Reprints: http://www.sagepub.com/journalsReprints.nav Permissions: http://www.sagepub.com/journalsPermissions.nav

>> Version of Record - Feb 17, 2014 OnlineFirst Version of Record - Dec 20, 2013 What is This?

Downloaded from cpt.sagepub.com at TEXAS SOUTHERN UNIVERSITY on October 8, 2014

Cardiovascular Pharmacology Core Review

The Therapeutic Role of Niacin in Dyslipidemia Management

Journal of Cardiovascular Pharmacology and Therapeutics 2014, Vol. 19(2) 141-158 ª The Author(s) 2013 Reprints and permission: sagepub.com/journalsPermissions.nav DOI: 10.1177/1074248413514481 cpt.sagepub.com

William E. Boden, MD, FACC, FAHA1, Mandeep S. Sidhu, MD, MBA, FACC1, and Peter P. Toth, MD, PhD, FACC, FAHA2

Abstract There is abundant epidemiologic evidence to support the independent, inverse relationship between low levels of high-density lipoprotein cholesterol (HDL-C) and incident cardiovascular (CV) risk, the clinical importance of which is underscored by the high prevalence of low HDL-C in populations with coronary heart disease (CHD), with or without elevated levels of lowdensity lipoprotein cholesterol (LDL-C). The National Cholesterol Education Program recommended that optimal treatment for high-risk patients includes both lowering LDL-C and non-HDL-C to risk stratified levels and raising HDL-C when it is